Mankind Pharma to acquire 70% stake in Belgium's ACTx for EUR 48M

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹2347.60

prior close

₹2349.90

announcement price

After-mkt

timing

Nifty Midcap 150market-0.1%-3.0% vs market

Pharmaceuticals peers, median of 173sector+0.1%-3.2% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Midcap 150 and 3.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.9

15m

-0.8

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1-0.1-3.0+0.1-3.2

Next day

-4.0-1.2-2.8-1.2-2.8

-2.6-2.6-0.1-3.0+0.3

-3.1-3.3+0.3-3.9+0.8

-5.8-5.3-0.4-5.0-0.7

-1.5-4.3+2.8-3.9+2.4

+6.1-3.2+9.2-0.9+7.0

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma will acquire 70% stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million in cash, via its Dutch subsidiary. ACTx develops next-generation CAR-T cell therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. Mankind will invest up to EUR 50 million into its Dutch arm to fund the deal in tranches. The move marks strategic entry into advanced cell therapy.

Likely market impact

Marks Mankind's entry into advanced cell therapy, diversifying beyond core pharma. Deal size is moderate. Long-term R&D play with no near-term revenue impact.